Skip to main content

Table 1 Clinical characteristics of prostate cancer patients treated with ADT (n = 280)

From: Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer

ParametersNo. of patients(%)
Age (median, interquartile range), years76 (67.25–79)
PSA (median, interquartile range), μg/L91.20 (29.26–189.00)
Gleason Score
  < 728 (10.00)
 3 + 442 (15.00)
 4 + 368 (24.29)
 889 (31.78)
 950 (17.86)
 103 (1.07)
Metastasis
 No149 (53.21)
 Yes131 (46.79)
Risk Stratification
 Low1 (0.36)
 Intermediate26 (9.28)
 High253 (90.36)
PNI (median, interquartile range)50.05 (46.46–53.55)
Progression-free survival129 (46.07)
Cancer-specific survival63 (22.50)
Overall survival78 (27.86)
Types of ADT
 Orchiectomy + anti-androgen therapy272 (97.14)
 LHRN-a + anti-androgen therapy8 (2.86)
 Follow-up time (median, interquartile range), months46.00 (31.00–59.00)
  1. Abbreviations: PSA Prostate-specific antigen; PNI Prognostic nutritional index; ADT Androgen deprivation therapy; LHRN-a Luteinizing hormone releasing hormone-a